Genelux Corporation · NASDAQ:GNLX
Genelux — Investor Presentation (March 2025)
43 slides from Genelux's investor presentation, Mar 25, 2025
Slide 1: Redefining Immuno-Oncology
(yeENELUX Redefining Immuno-Oncology Corporate Presentation March 2025 / J
Slide 2: Disclaimer
Disclaimer This contains forward-look within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21£ of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections, about Genelux Corporation (“Genelux,” the “Company,
Slide 3: Highlights
Highlights Olvi-Vec: late-stage Clinical Program focused on Platinum Resensitization in Multiple Indications 2JA Ongoing pivotal Phase 3 trial in late-stage platinum resistant/refractory ovarian cancer (PRROC) 4 al Ongoing Phase 2 trial via systemic administration in recurrent non-small cell lung ca
Slide 4: A Maturing Modality with Phase Companies Validating OV Potential
A Maturing Modality with Phase 3 Companies Validating OV Potential @eNeLux = Systemic Next Generation Delivery Regional & Systemic Administration Phase 2 Ovarian Cancer Limitations of 1s‘ Gen Viruses ; Phase 1b Solid Tumors Limited to local delivery and scope of addressable cancers = ANIGEN 'o) FDA/
Slide 5: Program Builds on Completed Trials to Exploit Competitive Advantages
Program Builds on Completed Trials to Exploit Competitive Advantages > Therapy (platinum resensitization in multiple indications) 3 Upcoming Trial Readouts have Potential to Redefine: e 7 fi > Modality (systemic administration of an oncolytic virus) . Gare A aH ated Olvi-Vec Indication Design Precli
Slide 6: The Most Advanced Non-local Delivery Oncolytic Immunotherapy
The Most Advanced Non-local Delivery Oncolytic Immunotherapy Olvi-Vec: 7 Completed Clinical Trials (>150 Patients) Physician-preferred routes of delivery Regional and Systemic Administration to preferentially locate, colonize and destroy tumor cells, including metastatic disease IV therapy currently
Slide 7: Regional Administration Program: Ovarian Cancer
Regional Gs Administration ENELUX Program Ovarian Cancer
Slide 8: Ovarian Cancer Program: Regional (Intraperitoneal) Delivery
Ovarian Cancer Program: Regional (Intraperitoneal) Delivery Key Takeaways IN * Phase 1 tested condensed dosing schedule and demonstrated tolerability with evidence of anti- tumor activity Phase 2 demonstrated promising Overall Response Rate (ORR) and Progression Free Survival (PFS), and clinical rev
Slide 9: Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results
Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance. Key Inclusion Criteria Multi-center, randomized open-label" | rimaryEndpoint =| n=186 » High-grade serou
Slide 10: Completed Phase Ib Anti-tumor Activity as Monotherapy Leading into Combination
Completed Phase Ib Anti-tumor Activity as Monotherapy Leading into Combination Olvi-Vec Monotherapy! ~ Patient Background & Study Treatment » Heavily pre-treated PRROC patients with documented progressive disease * Cohort 1 received a single cycle of intraperitoneal delivery on 2 consecutive days; t
Slide 11: Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy
Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy Heavily Pretreated Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer [pees] | Keyinclusion Criteria Interventional Single Group Assignment 1. 2020 Digital Annual Meeting of International n=27 Gynecologic Cancer Society
Slide 12: Phase 2: Clinically-Meaningful Responses in Heavily Pretreated Patients
Phase 2: Clinically-Meaningful Responses in Heavily Pretreated Patients Overall Response Rate (ORR), including Complete Responses (CR) & Partial Responses (PR), and Progression-Free Survival (PFS)* Key Clinical Takeaways IN ORRby —Durationof + ORR by Median ret Survival (OS) RECIST1.1~ Response CA-1
Slide 13: Demonstrated Deep and Durable Tumor Shrinkage
Demonstrated Deep and Durable Tumor Shrinkage Tumor Shrinkage » PPP PP PP PP PP oP oP oP oP oP oF oP oP of oP oF 100 133.24 58 81 62 132 19 46 45 53 129 31 253 70 124 48 145 65 138 83 82 12 Key Clinical Takeaways 80 Baseline tumor burden as Sum of Longest Diameter of target lesions (mm) Refractory p
Slide 14: Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness”
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, 15B-01: Stage IIIB papillary serous ECOG: 0 BRCA negative PD-L1 negative Overall Survival: 23.2 Months achieved PFS exceeding any prior lines 15B-15: * Stage IIIB high-
Slide 15: Durable Survival Benefit
Durable Survival Benefit gnosi: with each jive Line Historical Data? ELAHERE? b 2rline 24.1mOs (95% 1, 17.8-24.4) | oar ae 3 line 12.9m0S __(95% Cl, 10.4-14.6 : Key Clinical Takeaways a line 9.8 mOS (95% Cl, 7.1-12.25) | 11.6 mos 1.0 4 5" line Not reported N/A Bookman et al., Gynecol Oncol. 2017;146
Slide 16: Phase 2 Compared to Approved Standard of Care in Earlier Lines
Phase 2 Compared to Approved Standard of Care in Earlier Lines IN Key Clinical Takeaways Olvi-Vec addresses a broad and underserved pool of patients * Olvi-Vec trial inclusion criteria allows patients regardless of (i) tumor biomarkers, (ii) platinum refractory tumors, or (iii) number of prior lines
Slide 17: Self Launch Olvi-Vec for Ovarian Cancer in the US
Self Launch Olvi-Vec for Ovarian Cancer in the US Partnerships eS Leverage partnership with GOG Foundation + Preeminent US-based cooperative group in Gynecologic Oncology Composed of leading KOLs in the field Partners in the OnPrime/GOG-3076 Phase 3 registrational trial Drivers of Market Penetration
Slide 18: Systemic Administration Programs: Lung Cancers
Systemic G) Administration ENELUX Programs Lung Cancers
Slide 19: Systemic Administration Demonstrated Dose-dependent OS Benefit
Systemic Administration Demonstrated Dose-dependent OS Benefit Key Clinical Takeaways Demonstrated feasibility and clinical benefit of multiple IV cycles * Median 5 prior lines of therapy * Regimen: various dosing levels and schedules (typically over 4-6 months) * Duration of Treatment (DoT): Higher
Slide 20: Systemic Administration + Chemo Generated Encouraging Data
Systemic Administration + Chemo Generated Encouraging Data Key Clinical Takeaways IN Anti-tumor effect of IV Immunochemotherapy + High and Condensed Dosing (single cycle: bolus infusion on 5 consecutive days) + Well tolerated: No DLT or MTD reached » Monotherapy: Anti-tumor effects * Combination the
Slide 21: Systemic Administration Program
Systemic Administration Program Key Takeaways » Ongoing Clinical Trials +» Funding commitment by Newsoara of the US-based Genelux Phase 2 trial in Sponsor Trial Sites Indication fare (Peiteniis || (Rameloamzit Status Stage (est.) n NSCLC Recurrent/platinum * Genelux has worldwide commercial & NEWSOA
Slide 22: Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer
Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer Heavily Pretreated Patients with Platinum-Relapse or Platinum-Refractory Small Cell Lung Cancer Key Inclusio: ria After receiving platinum containing chemotherapy scheme +/- immunotherapy, platinum containing chemotherapy scheme +/- anlotinib and
Slide 23: Phase 1b SCLC Systemic Administration - Interim Data Readout
Phase 1b SCLC Systemic Administration - Interim Data Readout As of February 19, 2025 Key Takeaways IN Data is supportive of Olvi-Vec potentially being a platinum resensitizing agent beyond ovarian cancer and underscores the current clinical development strategy + Initial dose escalation cohorts achi
Slide 24: Phase 2 Trial in Recurrent Non-small Cell Lung Cancer
Phase 2 Trial in Recurrent Non-small Cell Lung Cancer Patients with Non-small Cell Lung Cancer after First Progression while on Front-Line Immune Checkpoint Inhibitor-based Maintenance Multi-center, dose escalation, open-label =~30 Key Inclusion Criteria Three Dose Escalation Cohorts . Olvi-Vec and
Slide 25: Industry Collaboration with Newsoara BioPharma Co., Ltd
Industry Collaboration with Newsoara BioPharma Co., Ltd @ene_uxD NEWSGARA ae MEH Benny Li, PhD Founder and Chief Executive Officer 20+ yrs. global and China local pharma Former VP, GM of Takeda China Development Center and SVP, Executive GM of R&D at Hansoh Pharmaceuticals Former Head of Clinical De
Slide 26: Intellectual Property: Market Exclusivity & Freedom to Operate
Intellectual Property: Market Exclusivity & Freedom to Operate Patent Portfolio: 20 issued patents, 1 allowed application and 7 pending applications; Olvi-Vec covered by Composition of Matter (2031*) and Manufacturing (2038) Strong IP ; & ~~ Olvi-Vec: No third-party royalties due Regulatory Designat
Slide 27: Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch
Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch Key Takeaways IN Facilities and Operations based in Southern California GMP Manufacturing * Large-scale manufacturing process _ . * Capacity for clinical studies and commercial launch needs Translational Research * Clinical Science
Slide 28: Accomplished Leadership Team
Accomplished Leadership Team Executive Team Board of Directors THOMAS ZINDRICK, JD AMGEN aefomics Chairman of the Board DNX hoist Myers Sub JAMES L. TYREE, MBA 2 Lead Independent Director CE) Abbott Thomas Zindrick, JD Matthew Pulisic, MBA Paul Scigalla, MD, PhD Sean Ryder, JD hf Chief Executive Off
Slide 29: Genelux Has Executed on Multiple Milestones and is Positioned for the Future
Genelux Has Executed on Multiple Milestones and is Positioned for the Future Regular Cadence of Important Program Milestones - 3 Upcoming Trial Readouts have Potential to Redefine: Therapy (platinum resensitization in multiple indications) Modality (systemic administration of an oncolytic virus) ~ >
Slide 30: Appendix
(yeENELUX Redefining Immuno-Oncology Corporate Presentation | March 2025 Appendix
Slide 31: Olvi-Vec Seeks to Unleash Immune System Against Cancer
Olvi-Vec Seeks to Unleash Immune System Against Cancer Key Takeaways IN Olvi-Vec Innate Adaptive Immune Activation Immune Activation viral infection Olvi-Vec is being developed as a robust immune modulator that utilizes a triple mode of action to : mount a personalized attack against (neo)antigens c
Slide 32: Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance
Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance Olvi-Vec-Induced Hot Tumor Pro-therapeutic gene expression aon Chemotherapy synergy [VIRO-15 Monotherapy Data] 4 Positive regulation of T-cell activa WE i va Immunogenic cell death and i and trafficking? \ presentation of oncogenic ne
Slide 33: Accomplished Clinical Advisory Board
Accomplished Clinical Advisory Board Robert Holloway, MD areola CHAIRMAN Cancer institute Chief Medical Officer, Vanium Sau Robert Coleman, MD Albert A. Mendivil, MD Deputy Director of versity of Thomas J. Herzog, MD David M. O'Malley, MD Alan Forsythe, PhD ©5980 Dr. Holloway is the principal invest
Slide 34: Olvi-Vec-primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker
Olvi-Vec-primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker Rapid, Common and Durable Responses CA-125 Decrease o All PRROC Patients: 96% (25/26) o Platinum refractory patients: 85% (11/13) ORR by CA-125 o All PRROC Patients: 85% (22/26) o Platinum refractory patients: 85% (11/13) Best
Slide 35: Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness”
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines 15B-15: Pt.15B-15 (primary platinum-refractory HGSOC) Stage IIIB high- grade serous 160 5000 + ECOG:0 J Start of Chemo/Bevacizumab
Slide 36: Olvi-Vec Demonstrated Oncolysis and Immune Activation
Olvi-Vec Demonstrated Oncolysis and Immune Activation Data from Phase lb Monotherapy portion of VIRO-15 trial Key Takeaways IN Olvi-Vec monotherapy shows decreased tumor cells and increased immune activation * Olvi-Vec treatment was able to dramatically decrease or eliminate tumor cells in multiple
Slide 37: CD8+ T-cells: Infiltrating Lymphocytes are Prognostic for Response/Survival
CD8+ T-cells: infiltrating Lymphocytes are Prognostic for Response/ Survival Pt# 15A-16 Pt# 15A-18 Pt# 15A-23 Pre-Olvi-Vec Post-Olvi-Vec (prior to subsequent chemotherapy) Endogenous TiLs (intra-tumoral and stromal) are very low in ovarian Pt# 15A-23 cancer, i.e, immunologically ‘cold’. WARE H 107 6
Slide 38: Long-lasting, Tumor-specific T cell Response Corresponds to Tumor Reduction
Long-lasting, Tumor-specific T cell Response Corresponds to Tumor Reduction Data from Phase Ib Monotherapy portion of VIRO-15 trial 0000 Confirms tumor-antigen presentation Case Report (Pt #15A-05) & immune activationimemory Key Ta keaways >» Heavily pre-treated: > « 9 prior regimens of chemo+Avasti
Slide 39: Olvi-Vec Demonstrated Anti-Tumor Response & Disease Control Observed
Olvi-Vec Demonstrated Anti-Tumor Response & Disease Control Observed Data from Phase lb Monotherapy portion of VIRO-15 trial Target lesion SLD change overtime Individual target lesion change 40 w 38 x 8 » 6 rn i) @ p S gs rc s a = 3 & = ro) rt & 2 c = S b o a lesion size from b: x 8 Patient ID # Ove
Slide 40: Choice Platform Library: 500+ Vectors with 110+ Transgenes
Choice Platform Library: 500+ Vectors with 110+ Transgenes Engineered and selected clonal isolated (non-GMO) viral strains identified from in vitro and in vivo selection criteria Virus-encoded transgenes Therapeutic Cell Growth & Differentiation Regulators Hormones Genes Metastasis Suppressor Genes
Slide 41: Olvi-Vec & cisplatin demonstrate activity in animal models with platinum-resistant cancer lines
Olvi-Vec & cisplatin demonstrate activity in animal models with platinum-resistant cancer lines Synergistic and durable antitumor activity Ovarian Cancer Melanoma (OVCAR-3 cell line) (WM266.4 cell line) Poy No treatment. “=-Olvi-Vec alone + Untrested control cisplatin -i-OlviVec + cisplatin 3500) |
Slide 42: Olvi-Vec: Ideal Backbone for Combination Therapy
Olvi-Vec: Ideal Backbone for Combination Therapy Converts Tumor Microenvironment to Inflammatory “Hot Spot” NCTO1443260/TUE Study of acute i ratory cytokines (Thi-type related) Fold-change from Baseline VIRO-15 Study - Massive inflammatory Baseline response after (C1D24) Baseline W1D5 W2D10 W3D17 si
Slide 43: V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical
V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical VACT Key Trial Takeaways >» V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT. V2ACT Immunotherapy, Vaccination increases the numbers of neoantigen-s